ERO1A and neoplasm: The data above revealed that ERO1α significantly contributed to tumor progression and ferroptosis resistance, encouraging us to explore whether inhibition of ERO1α in combination with ferroptosis inducers could synergistically inhibit the growth of mTORC1-activated cells in vivo.